Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Partnerships: PFE for AD and BIIB for MS.
Growing BIGGER and FASTER than NFLX !
Overstock going after 75% of Goldman Sachs revenue using blockchain. Watch the conference call video $100+
Which Monday do we open up $10?
Not a question of if, but when?
OSTK should buy ENVV with its license for digital trading and Global Payment and Financial Trading Platform making it easy to move from digital currencies to stocks and back again.
Amazing Information on this video of conference call. Imo I think this goes to $100+
BILLION DOLLAR drug for Rhett alone:
Around 200,000 cases in US alone
Anavex can charge $300,000
$1,000,000,000/ $300,000 = only 33,333 patients of 200.000
Multi billion drug easily
A Tiny 172 million market Cap, Ridiculous.. It is if all drugs have failed trials. Which is far from reality. Impatient investors lose money. We all know they are waiting for new FDA protocols to start trials. I will wait and buy more from those inpatient ones.
TINY FLOAT. Could take this to $50 easily if big money wants to make a ton. See the annual high.
This drives HMNY much higher:
Institutions are buying 100m convertible that allows them to convert to stock at a price at $12.50. You know they will run the stock to $25 to easily double their investment imo.
FDA designed phase 2/3 to mimic results of super responders in large trial is being designed, so I am buying,
Also if Rett is successful its a billion dollar homerun.
Crazy not to BUY on this news, Just the start.
AVXL should go to $30+ now
I will be BUYING throughout the day, 104 week data is a long time for AD patients not to drop off a cliff or worse.
Amazing News ! BILLIONS will come to AVXL replacing SOC for ALzheimers. No Drug EVER, EVER showed these results !!
Next week could be AVXL run.
Upcoming Schedule:
CTAD November 4
Post CTAD Noble Capital Markets/Anavex Non Deal Roadshows. 4 Dates across the country:
November 6, 2017 - November 7, 2017
- AVXL - Anavex Life Sciences - NEW YORK
November 8, 2017 - November 8, 2017
- AVXL - Anavex Life Sciences UTAH / - DENVER
November 9, 2017 - November 9, 2017
- AVXL - Anavex Life Sciences - NORTHERN CALIFORNIA (SAN FRANCISCO)
November 10, 2017 - November 10, 2017
- AVXL - Anavex Life Sciences - SO CAL (LOS ANGELES/SAN DIEGO)
November 13 Neuroscience 2017 presentation on 273 for Rett
November 14 Neuroscience 2017 presentation on 273 for Parkinsons
November 15 Neuroscience 2017 presentation on 273 for Anglemans syndrome
Just beginning, if you have done your homework.
Buying/Holding for one big reason. Any failure can't come until a trial is run. Phase 2/3 trials haven't even started. So until then, the chances of good news is higher than bad.
Presenation Schedule:
CTAD November 4
Post CTAD Noble Capital Markets/Anavex Non Deal Roadshows. 4 Dates across the country:
November 6, 2017 - November 7, 2017
- AVXL - Anavex Life Sciences - NEW YORK
November 8, 2017 - November 8, 2017
- AVXL - Anavex Life Sciences UTAH / - DENVER
November 9, 2017 - November 9, 2017
- AVXL - Anavex Life Sciences - NORTHERN CALIFORNIA (SAN FRANCISCO)
November 10, 2017 - November 10, 2017
- AVXL - Anavex Life Sciences - SO CAL (LOS ANGELES/SAN DIEGO)
November 13 Neuroscience 2017 presentation on 273 for Rett
November 14 Neuroscience 2017 presentation on 273 for Parkinsons
November 15 Neuroscience 2017 presentation on 273 for Anglemans syndrome
Certainly the next PYPL is PYDS.. Explosive growth for Years.
The NEXT PayPal ! Big growth with every quarter announced.
CTAD November 4
Post CTAD Noble Capital Markets/Anavex Non Deal Roadshows. 4 Dates across the country:
November 6, 2017 - November 7, 2017
- AVXL - Anavex Life Sciences - NEW YORK
November 8, 2017 - November 8, 2017
- AVXL - Anavex Life Sciences UTAH / - DENVER
November 9, 2017 - November 9, 2017
- AVXL - Anavex Life Sciences - NORTHERN CALIFORNIA (SAN FRANCISCO)
November 10, 2017 - November 10, 2017
- AVXL - Anavex Life Sciences - SO CAL (LOS ANGELES/SAN DIEGO)
November 13 Neuroscience 2017 presentation on 273 for Rett
November 14 Neuroscience 2017 presentation on 273 for Parkinsons
November 15 Neuroscience 2017 presentation on 273 for Anglemans syndrome
Compare: MZOR Market cap 1.5 Billion and ISRG's is 41 Billion. MZOR stock price can Double and still just be 3 Billion MC. But TRXC market cap only 411 Million !! Sky is the limit.
FYI, MZOR Market cap only 1.5 Billion and ISRG's is 41 Billion. MZOR stock price can Double and still just be 3 Billion MC.
WOW, MZOR Market cap only 1.5 Billion and ISRG's is 41 Billion. MZOR stock price can Double and still just be 3 Billion MC.
Longs are holding throughout 2018 for Retts and PD..Early 2019 for Alzheimers. Just one approval to help symptoms= BILLIONS, Worth the wait and buy at this cheap market cap.
This is very important information in response to the abstract. Thank you. If Anavex 273 helps to create myelin by maturing OL, the sky is the limit.
How important is this differential over DM? "Anavex 2-73 also accelerates OPC maturation to OL".
My favorites for 2017: VERI, AVXL and RIOT.
My favorites for 2017 are RIOT and AVXL.
Starting today, Facebook is offering users the ability to choose PayPal as the funding source for peer-to-peer payments - and it can even be set as the default, PayPal tells us.
Starting today, Facebook is offering users the ability to choose PayPal as the funding source for peer-to-peer payments - and it can even be set as the default, PayPal tells us.
I agree. Would like PYPL to buy RIOT for the blockchain platform it can provide Paypal.
Watch RIOT Blockchain (RIOT)
Keep an eye on RIOT Blockchain (RIOT)
ENVV just announced major platform for financial trading of blockchain and cryptocurrency !
Will move up $1, $2 ,$3 and $4 per day. Refer to this post.
According to a report by Markets and Markets, the minimally invasive surgical instruments market is forecasted to reach a value of $21.47 billion by 2021